HOME >> BIOLOGY >> NEWS
New findings suggest colorectal cancer origins are different than previously thought

(June 12, 2003) Bethesda, MD - Colorectal cancer -- which includes cancers of the colon, rectum, anus, and appendix -- is the second-leading cause of cancer-related deaths in the United States. The mortality rate associated with this deadly disorder is well known. What is not clear, however, is whether colorectal cancer should be considered a local disease or a uniform organ disease that is not only localized at an individual site along the colorectum.

Background

There is ongoing controversy over whether mucosal hyperproliferation is involved in colorectal carcinogenesis. The hypothesis that was originally offered to explain the transition from normal mucosa to a benign epithelial neoplasm in which the tumor cells form glands or gland-like structures used a three stage process. At stage I, the proliferative compartment of the colorectal crypt, which is usually confined to the lower one-third of the crypt, extends upward and envelops the entire crypt. At stage II, the maximum of the proliferative compartment shifts to the upper portion of the crypt, and, at stage III, the total number of replicating cells in the crypt rises, leading to mucosal hyperproliferation and subsequently -- due to the influence of co-factors -- to a tumor. However, in patients with sporadic colorectal cancer, findings are debatable, and the scientific literature is divided into reports supporting or contesting the importance of the stage III defect for adenoma and carcinoma formation.

One possible explanation for this discrepancy in patients with sporadic colorectal cancer might be found in the techniques used to evaluate mucosal proliferation. Most of these methods are applied in vitro and are cytostatic, i.e., providing an estimate of only the fraction of proliferating cells in a particular phase of the cell cycle at a given moment. This information can be misleading, since it uses no measure of time (length of the cell cycle). The duration of the cell cy
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
17-Jun-2003


Page: 1 2 3 4

Related biology news :

1. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
2. Virginia Tech researchers to release findings on Smith River Project
3. New HIV findings
4. Stanford researchers findings may shed light on common, deadly birth defect
5. Briggs takes to the molecular level Darwins findings on plants sensing the direction of light
6. Latest findings on PCBs to be subject of June workshop at Illinois
7. Chlamydia in men now also linked to infertility new findings
8. New MS research shows remarkable findings
9. Scientists findings may lead to better understanding of how that sleep develops, matures
10. New findings are a window into the late stages of Lou Gehrigs disease
11. New findings bring mixed blessings to those looking to combat jet lag

Post Your Comments:
(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... May 26, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... the study protocol for the company,s Phase IIb trial ... Food and Drug Administration (FDA). The submission was made ... The Phase IIb study of ORMD-0801 for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Just the ... a long-standing unmet biomedical need does not guarantee immediate ... problem that has seen many prior failures is often ... acceptance and use is an irony that is often ... small, new start-up company, Asymmetrex has found ...
Breaking Biology Technology:TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
Cached News: